AC Immune (NASDAQ:ACIU) Raised to “Hold” at Zacks Research

Zacks Research upgraded shares of AC Immune (NASDAQ:ACIU) from a strong sell rating to a hold rating in a report issued on Tuesday,Zacks.com reports.

A number of other research firms also recently commented on ACIU. Wall Street Zen raised shares of AC Immune from a “hold” rating to a “buy” rating in a research report on Tuesday, May 13th. BTIG Research reissued a “buy” rating and set a $8.00 target price on shares of AC Immune in a research report on Monday. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, AC Immune currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

AC Immune Price Performance

ACIU stock opened at $2.38 on Tuesday. The company has a market capitalization of $238.98 million, a PE ratio of -4.10 and a beta of 1.61. AC Immune has a 12 month low of $1.43 and a 12 month high of $3.98. The firm’s 50-day moving average is $2.16 and its 200 day moving average is $1.98.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.05). The company had revenue of $1.65 million during the quarter, compared to analysts’ expectations of $1.98 million. AC Immune had a negative return on equity of 49.35% and a negative net margin of 174.94%. Sell-side analysts forecast that AC Immune will post -0.62 EPS for the current fiscal year.

Institutional Trading of AC Immune

Several institutional investors and hedge funds have recently bought and sold shares of ACIU. Dimensional Fund Advisors LP lifted its stake in AC Immune by 130.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 131,410 shares of the company’s stock valued at $355,000 after acquiring an additional 74,358 shares during the period. Northern Trust Corp acquired a new position in shares of AC Immune in the 4th quarter valued at $1,088,000. Jane Street Group LLC acquired a new position in shares of AC Immune in the 4th quarter valued at $66,000. Two Sigma Advisers LP acquired a new position in shares of AC Immune in the 4th quarter valued at $36,000. Finally, Squarepoint Ops LLC acquired a new position in shares of AC Immune in the 4th quarter valued at $118,000. 51.36% of the stock is currently owned by institutional investors and hedge funds.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.